New Mucon Series K2P Powered Iris Valve Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

New Mucon Series K2P Powered Iris Valve Technology

Mucon a division of Process Components Ltd has launched its new Series K2P electrically / pneumatically actuated range of Iris valves. The Mucon brand of Iris diaphragm valves has for over sixty years been associated with the control of powders, granules, capsules and pellets to the Pharmaceutical, Chemical and Food processing sectors.
Now in its second generation, the Series K2 Powered Iris Valves have been specifically designed for automatic and remote applications, complimenting the popular hand operated versions.

Developed for applications requiring a high level of hygiene, this valve utilises our patented, moulded diaphragm technology already employed throughout the K-Valve range.

Mucon Engineers have taken great care to balance customer requirements for quick disconnect, ease of cleaning and hygienic design with the requirements for reliability and control system integration.

All body parts are manufactured from 316 stainless steel, as standard. White moulded diaphragms of Natural Rubber, EPDM and Silicone are all manufactured from FDA approved materials.

The salient features and benefits of the new MUCON K2P valve are as follows;

  • Extensively used in the Pharmaceutical, Chemical and Food sectors
  • FDA approved diaphragm materials
  • Full product flow control
  • Non-Jamming
  • No mechanical parts in contact with the product
  • Slim Design
  • Electric and Pneumatic actuation
  • ATEX approved Cat. 1D / 2D
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
30%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
8%
All of the above.
45%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
FindPharma Custom Search

Click here